Bryan Cobb is a PR Medical Science Director and the Healthcare Delivery Innovation & Collaborations Lead at Genentech, U.S. Medical Affairs. Dr Cobb is focused on bringing novel biomarkers (digital and traditional) as well as innovative healthcare delivery tools into clinical trials and clinical practice with the goal of improving disease identification, patient treatment, and a patient’s overall quality of life.

Dr Cobb obtained a PhD in Medical Genetics at the University of Alabama at Birmingham and completed an American Board of Medical Genetics post-doctoral fellowship at NIH (National Human Genome Research Institute). He is a board-certified diplomate of the American College of Medical Genetics & Genomics.

Dr Cobb has held several roles at Roche, including Lead for the GE Healthcare partnership for Acute Care, Head of Medical Affairs for Roche, Director for Roche’s Molecular Centers of Excellence, and has over 15 years of experience across therapeutic areas (infectious diseases, genetics, neuroscience and oncology). He has published in key scientific journals, is a scientific reviewer for journals such as the Journal of Clinical Microbiology, and has served on several international scientific committees and working groups.

Leslie Addy has over 10 years of experience in the biotechnology industry. He is currently Director of Development Operations Innovation and Decentralized Clinical Trials at Amgen where he is driving innovation in development operations to align with the paradigm shift in the clinical trials execution model and emerging technologies and services. Mr Addy spent a majority of his working life in Information Systems and Digital Health and has a proven track record of identifying, testing and bringing new solutions to scale, in close collaboration with internal and external stakeholders. He has a Bachelor’s Degree in Computer Science and Mathematics and an MBA from the University of Southern California (USC).

Ardy Arianpour is CEO & Co-Founder of SEQSTER the leading healthcare technology company that puts the patient at the center of all their health data for more efficient clinical trials and improved healthcare outcomes for life science enterprises. With over 20 years of experience driving innovation in life sciences and digital health, Mr Arianpour is a visionary health tech executive. Before founding SEQSTER, he successfully launched numerous clinical and consumer-based genetic tests while serving as CCO of Pathway Genomics. Additionally, he held the position of SVP of Ambry Genetics, which was sold to Konica in 2017 for $1 Billion.

Mr Arianpour played a crucial role in the landmark SCOTUS decision that eliminated gene patents, expanding access to genetic testing. The launch of BRCA testing, in particular, significantly benefited patients and their family members nationwide.

Mr Arianpour received his BS in Biological Sciences from UC Irvine and an MBA from Marshall Goldsmith School of Management. He was a Medical, Marketing, and Media’s (MM&M) Top 40 Healthcare Transformer and San Diego Business Journal 40 under 40. Mr Arianpour is on the Digital Health Advisory Board of UCSD and Faculty for NextMed.Health.

Hila Barak, PhD, joined Gilead in 2021 as the Head of Oncology Clinical Science and Chief of Staff. Dr Barak serves as a key business partner to the Oncology Therapeutic Area Head and is immersed in strategic and operational elements for Gilead’s Oncology, leading and driving large projects, providing insight and access to the organizational strategy and direction.  Furthermore, she is directly responsible for building, managing, and mentoring a high-performance clinical science team to support clinical development programs across the Oncology Therapeutic Areas.

Dr Barak obtained her PhD from the Technion Institute in Israel and completed her post-doctoral fellowship at Washington University School of Medicine in St. Louis, where she performed distinguished research in the field of stem cells and renal development. After joining the pharmaceutical industry, she held a variety of roles in Regulatory Affairs, Global Medical Affairs and Clinical Science in multiple therapeutic areas as well as leadership roles, in leading strategic and operational projects for Clinical Oncology within R&D organization and provided strategic input for future clinical development of products in the pipeline. In her last role, Dr Barak served as the Global Clinical Lead for the MORPHEUS Combination Platform at Roche-Genentech, where she effectively led the overall strategy of more than 40 novel combinations tested across 10 solid tumor indications. In addition, she led several innovation initiatives to bring transformative treatment to patients with unmet medical need, including utilization of Artificial Intelligence tools to explore combination development and patient enrollment.  

Dr Barak is passionate about bringing transformative treatment to patients with cancer. 

Kimberly Barnholt has spent over 20 years in the healthcare industry in various roles spanning from academic research, to disruptive start-up, to global pharmaceutical company. In all roles, she has focused on bridging science, data, and operational disciplines to challenge the status quo and transform how we can deliver more impact for our patients. At Genentech, she has served as a Program Leader for cross-industry collaborations and cross-R&D data ecosystem transformation. Currently, Dr Barnholt is leading an Evidence Generation team of data strategists and clinical innovation and technology leaders to integrate new approaches to clinical trials.

Paul Bassett holds a Bachelor’s and a Master’s degree in Analytical Chemistry from Youngstown State University and a BSN degree from Kent State University. Mr Bassett has over 25 years of pharmaceutical drug development and clinical research experience, leading research teams to develop formulations for Zithromax, Caduet, Zyrtec, Zoloft, and anti cancer drugs such as Fludara, Doxorubicin, Daunorubicin, Cisplatin, and Methotrexate.

Currently, Mr Bassett is a Project Lead in Early Development Oncology Operations at Sanofi. His mission has been to create new ways of working through the complexities of operationalizing pre-candidate molecules for FIH studies, through study start-up and conduct processes.

Liz Beatty is a co-founder and chief strategy officer at Inato, a clinical trials platform which flips the traditional model and allows community sites to participate in the trials that are best aligned with their interests and that of their patients. Ms Beatty is focused on advancing Inato’s corporate strategy, developing partnerships and driving growth in North America. Previously, she headed digital clinical trials at Bristol-Myers Squibb, where she led digital innovation efforts across global clinical operations.

Sanjay Bharwaj is the Global Head of Clinical Technology Strategy & Operations at AbbVie where he leads an organization of technologists who enable AbbVie’s clinical trials data collection, data processing, and deliver submission-ready datasets. Prior to AbbVie, Mr Bharwaj was the Global Head of Clinical Data Management at Allergan. For over more than 2 decades in the Clinical Operations – Clinical Data and Technology domain, he has led global teams at several bio-pharma companies such as Biogen, Novartis, and Merck. He is active in industry conferences and forums focused on clinical data. As chair of the board at the Society for Clinical Data Management, he led the organization through its most challenging times during the COVID-19 pandemic. Mr Bharwaj has authored a number of clinical data related publications.

Jordan Brayanov, PhD is a Head of Digital Strategy within the Data Sciences Institute at Takeda. In this role, Dr Brayanov oversees the strategic development and deployment of Digital Health Solutions and oversees the design and implementation of Decentralized Clinical Trials within clinical programs across the Takeda R&D organization.

Prior to joining Takeda, Dr Brayanov served as Vice President of Research at Respiratory Motion — a leader in respiratory volume monitoring. Dr Brayanov’s experience and research focus are on the design, development, and deployment of patient-centric tools and measurement equipment, advanced data modeling, and data visualization. Dr Brayanov holds a PhD in Computational Neuroscience from Harvard University.

Xuemei Cai oversees a clinical group within Worldwide Research, Development & Medical at Pfizer focused on developing and qualifying digital endpoints in clinical trials. Dr Cai also provides medical, scientific, and compliance oversight for the Pfizer Innovation Research Laboratory, an industry-leading, state-of-the-art research facility located in Cambridge, MA providing groundwork that enables the analytical and clinical validation of technology prior or in parallel to deployment in interventional clinical trials.

Dr Cai is a founding member of the Digital Medicine Society. She received her MD from Harvard Medical School. She remains a practicing ICU physician and has taken her passion for multimodal monitoring and improving functional prognostication and measurement tools for patients, families, and providers into the digital medicine space to improve the clinical trial experience for participants and enable new therapies.

Taras is Executive Director, Innovation and Process Improvement within Global Development Operations at Amgen. His team leads efforts to transform how clinical trials are conducted at Amgen, with a focus on cycle time reduction and reducing barriers to participation for patients and investigators. Prior to his current role, Mr Carpiac served in leadership positions at Amgen within Study Operations and Data Management. He holds a BA in History from University of California, Berkeley, and an MBA from Golden Gate University.

Jennifer Levin Carter is a Venture Partner at Sandbox Healthcare and the Blue Venture Fund. Dr Carter currently serves on the Board and/or as a strategic advisor to multiple public and private precision medicine, healthcare services, digital health and life science companies. She is also Founder and CEO of a Precision Medicine company in stealth.

Prior to Sandbox, Dr Carter served as a Managing Director of JLC Precision Health Strategies, LLC and in 2018, she founded TrialzOWN™, Inc., a healthcare company in stealth, and was CEO until its prelaunch acquisition by the Flagship Pioneering company, Integral Health, (now Valo Health), in 2019. Prior to TrialzOWN™, she was the Founder and President of N-of-One®, Inc, serving as acting-CEO from 2008-2012, and Chief Medical Officer from 2012 until its acquisition by Qiagen (Market Cap $8B) in 2019.

Dr Carter holds a BS in Molecular Biophysics and Biochemistry from Yale University, an MD from Harvard Medical School, an MPH from Harvard School of Public Health, and an MBA from the Sloan School at Massachusetts Institute of Technology.